BREAKING: Largest Real-World Analysis of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Regression
After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported no evidence of disease (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization.
Full text:
https://paulcraigroberts.org/largest-real-world-analysis-of-ivermectin-mebendazole-in-cancer-patients-shows-84-4-clinical-benefit-nearly-half-report-cancer-disappearance-or-regression/
CONCLUSION
This first-ever real-world analysis of a ivermectin–mebendazole protocol in human cancer patients provides a compelling signal that demands serious attention. While these findings should be interpreted appropriately as hypothesis-generating evidence from a real-world clinical evaluation, the magnitude, internal consistency, and broad distribution of the observed effects cannot be ignored. We are not observing marginal changes or isolated responses—we are observing widespread self-reported disease control across a diverse cancer population, a substantial proportion of patients reporting complete disappearance of detectable cancer, and sustained adherence with favorable tolerability over time.
